Esperion Therapeutics Inc. (NASDAQ: ESPR): Stock Performance & Trend Analysis

In the last trading session, 7.34 million shares of the Esperion Therapeutics Inc. (NASDAQ:ESPR) were traded, and its beta was 0.90. Most recently the company’s share price was $1.95, and it changed around $0.08 or 4.28% from the last close, which brings the market valuation of the company to $332.32M. ESPR currently trades at a discount to its 52-week high of $3.40, offering almost -74.36% off that amount. The share price’s 52-week low was $0.70, which indicates that the current value has risen by an impressive 64.1% since then. We note from Esperion Therapeutics Inc.’s average daily trading volume that its 3-month average coming to 6.58 million.

Esperion Therapeutics Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.75. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ESPR as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Esperion Therapeutics Inc. is expected to report earnings per share of $Spirit Aerosystems Holdings, In for the current quarter.

Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information

Instantly ESPR has showed a green trend with a performance of 4.28% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -34.78% year-to-date, but still down -8.88% over the last five days. On the other hand, Esperion Therapeutics Inc. (NASDAQ:ESPR) is -10.96% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 87.81% from its current value. Analyst projections state that ESPR is forecast to be at a low of $12 and a high of $20.

Esperion Therapeutics Inc. (ESPR) estimates and forecasts

Esperion Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 118.61 percent over the past six months and at a 66.50% annual growth rate that is well above the industry average of 10.20%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 23.09%. Esperion Therapeutics Inc. earnings are expected to increase by 80.92% in 2024, but the outlook is positive 16.90% per year for the next five years.